CCM
FLNA

Coe Capital Management’s Filana Therapeutics FLNA Stock Holding History

Coe Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$427K Hold
5,000
– – 0.4% 69
2021
Q1 		$225K Buy
+5,000
New +$197K 0.23% 81

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Coe Capital Management's FLNA Position: Q2 2021 in Review

Coe Capital Management held its Filana Therapeutics (FLNA) position steady in Q2 2021 at 5,000 shares worth $427K. The position accounts for 0.4% of the portfolio, ranked #69.

Coe Capital Management first reported a position in FLNA in Q1 2021 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold FLNA as of Q2 2021.

  • Coe Capital Management held 5,000 shares of Filana Therapeutics worth $427K as of Q2 2021.
  • Coe Capital Management left its Filana Therapeutics share count unchanged in Q2 2021.
  • Filana Therapeutics made up 0.4% of Coe Capital Management's portfolio in Q2 2021, its #69 holding.
  • Coe Capital Management first reported a position in Filana Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2021.

Based on Coe Capital Management's 13F filing for Q2 2021, filed 22 Jul 2021.